AUC analysis was then performed to determine if SOST levels improved the diagnosis of individuals with ongoing brain deposition, either alone or in combination with other known AD-related biomarkers (GFAP, t-tau, p-tau181, p-tau231, Aβ40, Aβ42 and Aβ42/Aβ40 ratio). Here, GFAP is linked to Alzheimer disease.